Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Safety, Tolerability and Proof of Concept Study to Evaluate the Use of ANXV (Recombinant Human Annexin A5 Protein) in the Treatment of Patients With Either Diabetic Retinopathy or Recent Onset Retinal Vein Occlusion

NCT07259928 is registered in ClinicalTrials.gov with Annexin Pharmaceuticals AB as lead sponsor.

NCT NCT07259928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07259928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Safety, Tolerability and Proof of Concept Study to Evaluate the Use of ANXV (Recombinant Human Annexin A5 Protein) in the Treatment of Patients With Either Diabetic Retinopathy or Recent Onset Retinal Vein Occlusion
Lead sponsor
Annexin Pharmaceuticals AB
Phase
Phase 2
Overall status
Recruiting
Start date
November 7, 2025
Completion date
July 31, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-proliferative diabetic retinopathy, retinal vein occlusion